!!Akos Heinemann - Curriculum Vitae
\\
__Positions and Education__
\\
*Since 2021 	Director of Otto Loewi Research Center, Medical University of Graz, Austria\\
*Since 2010 	Head of Division of Pharmacology, Medical University of Graz, Austria \\
*2009	Full Professor of Pharmacology, Medical University of Graz\\
*2003	Board Certified Specialist in Pharmacology, Austrian Med. Association \\
*2000	Habilitation in Pharmacology and Associate Professorship, Institute of Pharmacology, Karl Franzens University of Graz Medical School, Graz, Austria\\
*1998 - 1999	Post-doctoral Research Fellow, Imperial College School of Medicine, London, UK (Prof. T.J. Williams)\\
*1993 - 1998	Research Fellow, Institute of Pharmacology, Karl Franzens University of Graz Medical School, Graz, Austria\\
*1992 - 1995	Fellow in Internal Medicine (Graz), Surgery (Kalwang) and Dermatology/Allergology (Graz), Austria\\
*1991	M.D. degree\\
*1984 - 1991	Medical student, Karl Franzens University of Graz Medical School, Graz, Austria
\\
__Career-related activities__
\\
*Since 2013 	Member and since 2023 Chairman of the Academic Senate of the MUG\\
*Since 2004 	Board member of the Ethics Committee of the MUG\\
*2006 - 2024 	Coordinator of the “PhD Program Molecular Medicine” at the MUG\\
*Since 2006 	Advisory board member for Astra Zeneca, Amgen and Bayer\\
*2010 - 2021 	Speaker of the FWF-funded “Doctoral College MOLIN” at the MUG\\
*2014 – 2023 	Board member of the Austrian Science Fund FWF\\
*Since 2022 	Member of the Drug Evaluation Committee of the Austrian Federal Social Insurance Services\\
*Since 2022 	President of the Austrian Pharmacological Society
\\
__Research metrics__
\\
*Number of published full articles: 211, cumulative impact factor: 1196, total citations: 8786, H-index: 55\\
*Invited referee for >40 scientific journals and >10 funding organizations\\
*Main supervisor of 16 PhD thesis (plus 4 ongoing)
\\
__Research funding__
\\
*2021 - 2025	 FWF, DOC129, Role of succinate and GPR91 in lung fibrosis, € 220,000  \\
*2018 - 2022	FWF, DOC31, Role of prostaglandin receptors in the placenta, € 220,000  \\
*2017 - 2020	Austrian Academy of Science (ÖAW) DOC, Role of 15-prostaglandin dehydrogenase in idiopathic pulmonary fibrosis, € 110,000\\
*2014 - 2018	FWF, P26185, Imatinib as a novel prostaglandin-releasing drug (with R. Schuligoi), € 330,000 \\
*2013 - 2018	FWF, P25531-B23, Role of PGE2 and EP receptors in the pulmonary endothelial function (with V. Konya), € 327,000
*2015 - 2018, 	Austrian Academy of Science (ÖAW) DOC, Short chain fatty acids as regulators of eosinophil function, € 110,000 \\
*2012 - 2021	FWF and MUG (DK-MOLIN), W1241, Leukocyte trafficking and inflammatory mediators, € 820,000\\
*2010 - 2015	FWF, P22521, Prostaglandin receptors in the treatment of allergy, € 310,000\\
*2012 - 2015	OeNB, 14263, Effect of the novel lipid-lowering therapy niacin plus laropiprant on platelet function, € 89,000\\ \\[{ALLOW view All}][{ALLOW edit aheinemann}][{ALLOW upload aheinemann}][{ALLOW comment All}]